May 6, 2026 · Arthritis & rheumatology (Hoboken, N.J.) · DOI: 10.1002/art.70206

Therapeutic targeting protein kinase CK2 ameliorates lupus nephritis by modulating neutrophil infiltration and neutrophil extracellular trap formation

Listen to this summary

The authors investigate the therapeutic potential of the protein kinase CK2 inhibitor CX-4945 in treating systemic lupus erythematosus (SLE) by examining its effects on neutrophil dysregulation and neutrophil extracellular trap (NET) formation. Their findings demonstrate that CX-4945 significantly improves renal function and reduces inflammation in murine models of lupus, suggesting that CK2α is a promising therapeutic target for SLE and related autoimmune conditions.

Minghua Zhan, Shiran Dong, Zhou Bai, Honglin Xu, Chaotao Hu, Lufan Fu, Ke Zhang, Mei Chen, Yulin Yuan, Jinliang Yang, Fang Wang, Fei Xiao, Xuan Zhang, Yudong Liu

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play